NEW DATA TO BE PRESENTED
New MammaPrint + BluePrint Data at the 2026 ASCO® Meeting
BREAST CANCER TREATMENT RESEARCH
Explore Our Data & Trials
ABOUT
About the 2026 ASCO® Annual Meeting
The American Society of Clinical Oncology Annual Meeting (ASCO), taking place May 29th – June 2nd, 2026, in Chicago, Illinois, brings together oncology professionals, researchers, and industry leaders from around the world to explore the latest advances shaping the future of cancer care. Agendia is proud to be part of this important event, connecting with clinicians and researchers to discuss how MammaPrint® + BluePrint® can help illuminate tumor biology, support personalized treatment planning, and guide more informed decisions for patients with early-stage breast cancer.
THE MAMMAPRINT + BLUEPRINT TEST SUITE
Analyze over a hundred relevant genes at once.
With the additional results of BluePrint, our molecular subtyping test, physicians gain an even broader genomic profile. From just one tumor block, you can interrogate over 150 genes containing information on a tumor’s level of aggression and potential for growth. These insights will serve as an essential resource for guiding your pre- and post-operative treatment strategies.
